K-METHYLATION
The Role of SETD6 Methyltransferase in the Modulation of Oncogenic Processes
| Coordinatore | BEN-GURION UNIVERSITY OF THE NEGEV
Organization address
address: Office of the President - Main Campus contact info |
| Nazionalità Coordinatore | Israel [IL] |
| Totale costo | 100˙000 € |
| EC contributo | 100˙000 € |
| Programma | FP7-PEOPLE
Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013) |
| Code Call | FP7-PEOPLE-2012-CIG |
| Funding Scheme | MC-CIG |
| Anno di inizio | 2013 |
| Periodo (anno-mese-giorno) | 2013-09-01 - 2017-08-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
BEN-GURION UNIVERSITY OF THE NEGEV
Organization address
address: Office of the President - Main Campus contact info |
IL (BEER SHEVA) | coordinator | 100˙000.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'My overarching goal is to investigate the importance of protein post-translational modification (PTM) networks in cancer. The signaling system defined by the PTM lysine methylation has recently emerged as a potential key regulator of cancer pathways. However, the mechanisms by which protein lysine methyltransferase (PKMT) enzymes contribute to cancer are poorly understood. I believe that characterizing novel PKMTs involved in the post-translational control of cellular proteins in cancer-relevant signaling networks can provide novel insights into the basic mechanisms of cellular transformation and identify new therapeutic targets for cancer treatment. SETD6 is a PKMT whose expression is dramatically down-regulated in a wide range of human cancers. During my postdoctoral work, we identified SETD6 as a key regulator of proliferation processes by modulating the NFKB signaling pathway and deciphered the molecular mechanism for this regulation. However, knowledge of the overall mode of action of SETD6 in cancer cells and of additional endogenous substrates of this enzyme is still obscure. The working hypothesis is that SETD6 methylation of key cellular substrates modulates cancer pathology. In this research I plan to utilize cellular, biochemical, genomic and a novel proteomic experimental platform I developed to elucidate the role of SETD6 in oncogenic processes and its involvement in the modulation of cellular signaling pathways linked to cancer; to characterize new methylation events catalyzed by SETD6; to understand how these marks are generated and under which specific physiological conditions; to elucidate how these marks are sensed by other cellular factors; and to decipher the molecular mechanisms that transduce these signals. I believe that this work will provide significant insight into the role of SETD6 in the modulation of oncogenic signaling processes with a long term plan to translate this knowledge into therapeutic applications in the future.'